ArticleHaematologica2016
Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?
Klaus Geissler et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it